Healthy Clinical Trial
Official title:
SpO2 Accuracy Comparison of Medline ReNewal Sensors to Arterial Blood CO-Oximetry
The purpose of this clinical study is to validate the SpO2 accuracy of the Medline ReNewal
pulse oximetry sensors during non-motion conditions over the range of 70-100% SaO2 as
compared to arterial blood samples assessed by CO-Oximetry. The end goal is to provide
supporting documentation for the SpO2 accuracy validation of the ReNewal sensors.
It is required that the Accuracy Root Mean Square (ARMS) performance of the ReNewal pulse
oximetry sensors will meet a specification of 3 or better in non-motion conditions for the
range of 70 - 100% SaO2 thereby demonstrating an acceptable SpO2 accuracy performance
specification.
An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and
to measure the blood oxygen saturation based on the amount of reflected or scattered
radiation. Pulse oximetry monitoring is considered a standard physiological measurement and
is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because
an arterial sample of blood is not required to make the measurement, the pulse oximeter can
provide non-invasive real time information. The clinical use of pulse oximeters has reduced
the frequency and necessity of invasive arterial blood sampling and has helped to improve
patient safety by providing continuous information to clinicians about patients' oxygenation
status.
The Medline ReNewal Reprocessed pulse oximeter sensors are indicated for single patient use
when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are
required. Following clinical use, each sensor is returned to Medline ReNewal where it is
cleaned, disinfected, and packaged for an additional clinical use. Each sensor is tracked
through the reprocessing cycle to monitor the number of times the sensor has been
reprocessed. The purpose of this study will be to test the accuracy of the SpO2 component of
the devices.
The SpO2 accuracy performance of ReNewal pulse oximetry sensors will be evaluated during
non-motion conditions over the range of 70-100% SaO2 and compared to arterial blood samples
assessed by CO-Oximetry. A minimum of 10 healthy adult subjects, ranging in pigmentation from
light to dark, will be enrolled in the study to meet the study design requirements defined by
International Organization for Standardization (ISO) 80601-2-61:2011 and by the FDA's
Guidance for Pulse Oximeters (March 4, 2013). The subjects will have an arterial catheter
placed in the radial artery to allow for simultaneous blood samples during stable plateaus of
induced hypoxic levels. The investigational devices will be placed on the fingers of both
hands for the test sites per the instructions for use. Simultaneous data collection will be
set up for each of the systems under test. For the data analysis, the control oximeter will
be used to assess the stability of each data point. Data that is found to be unstable will be
removed prior to the comparative analysis. Next the CO-Oximeter data will be reviewed to make
sure it does not contain any anomalous values such as elevated, low or inconsistent
carboxyhemoglobin (COHb), methemoglobin (MetHb), or total hemoglobin (tHb) data. Anomalous
values will be removed from the analysis prior to pairing of the SpO2 and SaO2 data. The
Accuracy Root Mean Square (ARMS) calculation is used to determine the SpO2 accuracy
performance. Success will be achieved with an ARMS of 3 or better showing equivalence to the
Gold Standard Reference CO-Oximetry providing documentation to support SpO2 accuracy claims
for the investigational device(s).
The study population will include 10-15 healthy non-smoking (or has refrained from smoking
for 2 days) competent adults 18-50 years of age. The subject selection will be an equitable
distribution of males and females of any race with varying skin tones including at least 2
darkly pigmented subjects or 15% of the subject pool, whichever is larger. Data collection
will occur over a 2-5 day period for this study population. Follow-up with each subject will
be conducted within 5 days following participation in the study and will be conducted via
telephone, text or email.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |